Drug trial tracks Long-Term safety for patients with rare immune diseases
Disease control
Recruiting now
This study is a follow-up for patients with rare, inherited immune system disorders who were in a previous trial of the drug leniolisib. It aims to check the long-term safety and side effects of continued treatment. Researchers will also monitor if the drug helps control disease …
Phase: PHASE2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC